title: Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation.
abstract: BACKGROUND
  Most transplant centers in the United States immunize patients awaiting liver transplantation against hepatitis B to prevent acquisition of hepatitis B through transplantation (de novo hepatitis B). A recent study showed that only 16% of patients with cirrhosis awaiting liver transplantation responded to single-dose recombinant vaccine.
  
  
  METHODS
  We studied the immunogenicity of double-dose recombinant vaccine in patients with cirrhosis awaiting liver transplantation.
  
  
  RESULTS
  Over a 4-year period (January 1994 to December 1997), 140 patients with cirrhosis without past or current hepatitis B infection were given double-dose recombinant vaccine (40 microg of Engerix B; SmithKline Beecham, Philadelphia, PA) at 0, 1 to 2, and 2 to 4 months. Hepatitis B surface antibody (HBsAb) was measured 1 to 3 months after completing vaccination. The response rate was 37%. However, HBsAb titers became undetectable in 35% of the responders during the post-transplant follow-up period. One hundred and thirty-seven patients underwent 144 liver transplantation procedures during the study period, and 3 patients developed de novo hepatitis B (2.2%). Livers transplanted from hepatitis B core antibody (HBcAb)-positive donors was the source of de novo hepatitis B in all cases. Two of the 3 patients who developed de novo hepatitis B were immunized before transplantation and one of them was a responder.
  
  
  CONCLUSIONS
  Although the response rate to double-dose recombinant vaccines is higher than the previously reported response to single-dose vaccine, it still is less than optimal.
authors.affiliation: Department of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Horlander
authors.forename: N
authors.initials: N
authors.lastname: Boyle
authors.forename: R
authors.initials: R
authors.lastname: Manam
authors.forename: M
authors.initials: M
authors.lastname: Schenk
authors.forename: S
authors.initials: S
authors.lastname: Herring
authors.forename: P Y
authors.initials: PY
authors.lastname: Kwo
authors.forename: L
authors.initials: L
authors.lastname: Lumeng
authors.forename: N
authors.initials: N
authors.lastname: Chalasani
mesh_terms: D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D016896:Treatment Outcome; D014850:Waiting Lists
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D011994:Recombinant Proteins